Literature DB >> 21669298

Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.

Jacob Rozmus1, Kirk R Schultz, Kristin Wynne, Amina Kariminia, Preeti Satyanarayana, Mark Krailo, Stephan A Grupp, Andrew L Gilman, Frederick D Goldman.   

Abstract

Numerous mechanisms underlie chronic graft-versus-host disease (cGVHD), including skewing of Th1/Th2 cytokine expression. There are biological differences between early-onset and late-onset cGVHD. To test whether different Th1/Th2 cytokines are associated with early- or late-onset cGVHD, peripheral blood was collected from 63 children enrolled on the Children's Oncology Group Phase III trial ASCT0031 evaluating hydroxychloroquine therapy for newly diagnosed extensive cGVHD. mRNA expression of interferon (IFN)-γ and interleukin (IL)-2, -4, and -10 from stimulated peripheral blood mononuclear cells was evaluated by quantitative polymerase chain reaction. Early-onset cGVHD (n = 33) was characterized by decreased expression of IFN-γ and IL-2 mRNA after nonspecific phorbol 12-myristate 13-acetate-ionomycin stimulation. In contrast, late-onset cGVHD (n = 11) was characterized by decreased expression of IL-4 and IL-2 mRNA after anti-CD3 stimulation of T cells. Receiver-operating characteristic curve analysis revealed that IFN-γ expression was correlated with the absence of early cGVHD (area under the curve [AUC] = 0.77) and that IL-4 (AUC = 0.89) and IL-2 (AUC = 0.84) expression was correlated with the absence of late cGVHD. There was no correlation between cytokine expression and a specific immune cell subset. Increased expression of Foxp3 mRNA was seen in early-onset cGVHD and late controls. The different time-dependent cytokine profiles in patients with newly diagnosed cGVHD suggests that the mechanisms underlying cGVHD are temporally regulated. Although larger validation studies are needed, our data suggest that cytokine profiles have a potential use as biomarkers for the diagnosis of cGVHD.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669298      PMCID: PMC3190042          DOI: 10.1016/j.bbmt.2011.05.011

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  57 in total

1.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Authors:  David B Miklos; Haesook T Kim; Katherine H Miller; Luxuan Guo; Emmanuel Zorn; Stephanie J Lee; Ephraim P Hochberg; Catherine J Wu; Edwin P Alyea; Corey Cutler; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

2.  Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation.

Authors:  A Wechalekar; T Cranfield; D Sinclair; M Ganzckowski
Journal:  Clin Lab Haematol       Date:  2005-08

3.  Host-residual invariant NK T cells attenuate graft-versus-host immunity.

Authors:  Kyoko Haraguchi; Tsuyoshi Takahashi; Akihiko Matsumoto; Takashi Asai; Yoshinobu Kanda; Mineo Kurokawa; Seishi Ogawa; Hideaki Oda; Masaru Taniguchi; Hisamaru Hirai; Shigeru Chiba
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

4.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.

Authors:  Emmanuel Zorn; Haesook T Kim; Stephanie J Lee; Blair H Floyd; Despina Litsa; Sankari Arumugarajah; Roberto Bellucci; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

5.  Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  David Ritchie; Janet Seconi; Catherine Wood; Julie Walton; Victoria Watt
Journal:  Biol Blood Marrow Transplant       Date:  2005-09       Impact factor: 5.742

6.  Cytokine expression in human cutaneous chronic graft-versus-host disease.

Authors:  L A Ochs; B R Blazar; J Roy; E B Rest; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  1996-06       Impact factor: 5.483

7.  Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.

Authors:  Véronique Meignin; Régis Peffault de Latour; Julien Zuber; Armelle Régnault; Nicolas Mounier; Fabrice Lemaître; Hélène Dastot; Raphaël Itzykson; Agnès Devergie; Ana Cumano; Eliane Gluckman; Anne Janin; Antonio Bandeira; Gérard Socié
Journal:  Exp Hematol       Date:  2005-08       Impact factor: 3.084

8.  Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Katarzyna Bogunia-Kubik; Anna Mlynarczewska; Barbara Wysoczanska; Andrzej Lange
Journal:  Haematologica       Date:  2005-03       Impact factor: 9.941

9.  The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.

Authors:  Francesca Patriarca; Cristina Skert; Alessandra Sperotto; Francesco Zaja; Edmondo Falleti; Rosalba Mestroni; Francesca Kikic; Elisabetta Calistri; Carla Filì; Antonella Geromin; Michela Cerno; Renato Fanin
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

10.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

View more
  16 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

2.  Biomarkers in chronic graft-versus-host disease: quo vadis?

Authors:  D Wolff; H Greinix; S J Lee; T Gooley; S Paczesny; S Pavletic; F Hakim; F Malard; M Jagasia; A Lawitschka; J A Hansen; D Pulanic; E Holler; A Dickinson; E Weissinger; M Edinger; S Sarantopoulos; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

Review 3.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

4.  Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.

Authors:  Yoshihiro Inamoto; Paul J Martin; Sophie Paczesny; Laura Tabellini; Amin A Momin; Christen L Mumaw; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Barry E Storer; Samir Hanash; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-25       Impact factor: 5.742

Review 5.  Biologic markers of chronic GVHD.

Authors:  J Pidala; M Sarwal; S Roedder; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-07-22       Impact factor: 5.483

Review 6.  How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Authors:  Samantha M Jaglowski; Bruce R Blazar
Journal:  Blood Adv       Date:  2018-08-14

Review 7.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

8.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.

Authors:  Joseph Pidala; Carrie Kitko; Stephanie J Lee; Paul Carpenter; Geoffrey D E Cuvelier; Shernan Holtan; Mary E Flowers; Corey Cutler; Madan Jagasia; Ted Gooley; Joycelynne Palmer; Tim Randolph; John E Levine; Francis Ayuk; Fiona Dignan; Helene Schoemans; Eric Tkaczyk; Nosha Farhadfar; Anita Lawitschka; Kirk R Schultz; Paul J Martin; Stefanie Sarantopoulos; Yoshihiro Inamoto; Gerard Socie; Daniel Wolff; Bruce Blazar; Hildegard Greinix; Sophie Paczesny; Steven Pavletic; Geoffrey Hill
Journal:  Transplant Cell Ther       Date:  2021-04-06

9.  A combined biomarker and clinical panel for chronic graft versus host disease diagnosis.

Authors:  Joseph Pidala; Tara K Sigdel; Anyou Wang; Sue Hsieh; Yoshi Inamoto; Paul J Martin; Mary Ed Flowers; John A Hansen; Stephanie J Lee; Minnie M Sarwal
Journal:  J Pathol Clin Res       Date:  2016-11-29

10.  Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.

Authors:  Kirk R Schultz; Amina Kariminia; Bernard Ng; Sayeh Abdossamadi; Madeline Lauener; Eneida R Nemecek; Justin T Wahlstrom; Carrie L Kitko; Victor A Lewis; Tal Schechter; David A Jacobsohn; Andrew C Harris; Michael A Pulsipher; Henrique Bittencourt; Sung Won Choi; Emi H Caywood; Kimberly A Kasow; Monica Bhatia; Benjamin R Oshrine; Allyson Flower; Sonali Chaudhury; Donald Coulter; Joseph H Chewning; Michael Joyce; Sureyya Savasan; Anna B Pawlowska; Gail C Megason; David Mitchell; Alexandra C Cheerva; Anita Lawitschka; Shima Azadpour; Elena Ostroumov; Peter Subrt; Anat Halevy; Sara Mostafavi; Geoffrey D E Cuvelier
Journal:  Blood       Date:  2020-04-09       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.